Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants

Inclusion Criteria

• •1. Gestational age at delivery ≥32 0/7 weeks of gestation (earliest gestational age eligible for ABRYSVO vaccination) during the study period
• •2. Maternal age 18 to 50 years at pregnancy onset
• •3. At least 1 prenatal visit between pregnancy onset and 20 weeks of gestation
• •4. Continuous KPNC enrollment for a minimum of 30 days prior to pregnancy onset through to the date of delivery, with no more than a 1-month administrative gap in coverage